Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors

James M. Scheiman, MD
University of Michigan Medical School, Ann Arbor.

Correspondence: James M. Scheiman, MD, Associate Professor of Internal Medicine, Gastroenterology, University of Michigan Medical School, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109-0362; e-mail: [email protected]

The author has indicated that he has received grant or research support from AstraZeneca, Byk-Gulden, Pfizer, Merck, and SmithKline Beecham; has been a consultant for AstraZeneca, Merck, NitroMed, and McNeil; and is on the speakers’ bureaus of AstraZeneca, TAP, Merck, Wyeth, Pfizer, and Boehringer Ingelheim.

James M. Scheiman, MD
University of Michigan Medical School, Ann Arbor.

Correspondence: James M. Scheiman, MD, Associate Professor of Internal Medicine, Gastroenterology, University of Michigan Medical School, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109-0362; e-mail: [email protected]

The author has indicated that he has received grant or research support from AstraZeneca, Byk-Gulden, Pfizer, Merck, and SmithKline Beecham; has been a consultant for AstraZeneca, Merck, NitroMed, and McNeil; and is on the speakers’ bureaus of AstraZeneca, TAP, Merck, Wyeth, Pfizer, and Boehringer Ingelheim.

James M. Scheiman, MD
University of Michigan Medical School, Ann Arbor.

Correspondence: James M. Scheiman, MD, Associate Professor of Internal Medicine, Gastroenterology, University of Michigan Medical School, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109-0362; e-mail: [email protected]

The author has indicated that he has received grant or research support from AstraZeneca, Byk-Gulden, Pfizer, Merck, and SmithKline Beecham; has been a consultant for AstraZeneca, Merck, NitroMed, and McNeil; and is on the speakers’ bureaus of AstraZeneca, TAP, Merck, Wyeth, Pfizer, and Boehringer Ingelheim.